Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Expanded Access, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer

NCT01120561 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01120561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01120561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Expanded Access, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
Lead sponsor
Genentech, Inc.
Phase
Expanded access
Overall status
No longer available
Start date
May 31, 2010
Completion date
Not reported
Enrollment
Not reported
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer